Does Defactinib Interact with Avutometinib Potassium And Defactinib Hydrochloride?
CDI records a unknown classification for Defactinib and Avutometinib Potassium And Defactinib Hydrochloride. The stored summary is: Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inhibitor increases defactinib exposure [see Clinical Pharmacology (12.3) ], which may increase the risk of AVMAPKI FAKZYNJA CO-PACK adverse reactions. Defactinib is a CYP3A4 substrate. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
- Stored CDI classification
- Unknown
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Defactinib and your doctor is considering prescribing Avutometinib Potassium And Defactinib Hydrochloride (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider